Bayer AG Posts $13.24B Revenue, Flags €3.55B Litigation Hit
Bayer AG reported Q1 EPS of $0.17, slightly below forecasts, and revenue of $13.24 billion, beating estimates by $130 million while absorbing a €3.55 billion litigation charge. The FDA cleared its MEDRAD® MRXperion system for expanded field strength compatibility, broadening its MR injection system market potential.
1. First-Quarter Earnings
Bayer AG reported Q1 EPS of $0.17, missing the $0.18 consensus by 6%, while revenue reached $13.24 billion versus $13.11 billion expected, driven by strong pharmaceutical and agrochemical sales.
2. €3.55 Billion Litigation Charge
The quarter included a €3.55 billion charge related to weedkiller litigation, which turned what would have been a modest profit into a significant net loss for the period.
3. Balance Sheet and Valuation Metrics
As of quarter end, Bayer’s price-to-sales ratio stood at 0.81 and enterprise value to sales at 1.69, with debt-to-equity at 1.34 and a current ratio of 1.14, indicating elevated leverage but adequate short-term liquidity.
4. Expanded FDA Clearance for MRXperion System
Bayer secured FDA 510(k) clearance extending MEDRAD MRXperion’s compatibility across higher and lower magnetic field strengths, positioning the injector system for wider adoption in diverse MRI environments.